Advanced Search

    column
    Treatment Reform of Inoperable Stage Ⅲ Non-Small Cell Lung Cancer in the Immunotherapy Era
    GAO Ming, ZHOU Qing, WU Yi-long
    2022, 22(1): 1-3. DOI: 10.12019/j.issn.1671-5144.2022.01.001
    Abstract FullText HTML PDF
    GEMSTONE-301: Sugemalimab as a Consolidation Treatment After Concurrent or Sequential Chemoradiotherapy Improves the Survival of Patients With Unresectable StageⅢ Non-Small Cell Lung Cancer
    ZHU Zheng-fei, TAN Pei-xin
    2022, 22(1): 4-7. DOI: 10.12019/j.issn.1671-5144.2022.01.002
    Abstract FullText HTML PDF
    KEYNOTE-799: Pembrolizumab Plus Concurrent Chemoradiation in Unresectable, Locally Advanced, Stage Ⅲ Non-Small Cell Lung Cancer
    XIONG Le, LIU An-wen, CHEN Zhi-yong
    2022, 22(1): 8-13. DOI: 10.12019/j.issn.1671-5144.2022.01.003
    Abstract FullText HTML PDF
    From Attention to Neglecting: Thoughts of IMPACT Study
    YANG Fan, LIU Jia-qi
    2022, 22(1): 14-18. DOI: 10.12019/j.issn.1671-5144.2022.01.004
    Abstract FullText HTML PDF
    The Next Level: ADAURA, Adjuvant Osimertinib in Completely Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    QI Yi-fan, ZHONG Wen-zhao, ZHANG Jia-tao
    2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005
    Abstract FullText HTML PDF
    Application of Nivolumab Combined With Chemotherapy in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
    QIAO Gui-bin, FU Rui
    2022, 22(1): 26-29. DOI: 10.12019/j.issn.1671-5144.2022.01.006
    Abstract FullText HTML PDF
    Review of Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected StageⅠB~ⅢA Non-Small-Cell Lung Cancer
    CHEN Chun, ZENG Kang-hui
    2022, 22(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2022.01.007
    Abstract FullText HTML PDF
    The Application of Icotinib as Adjuvant Therapy for Stage Ⅱ~ⅢA EGFR-Mutant Non-Small-Cell Lung Cancer
    LIANG Nai-xin, MEI Shi-qi
    2022, 22(1): 34-37. DOI: 10.12019/j.issn.1671-5144.2022.01.008
    Abstract FullText HTML PDF
    2021 Research Advances in Lymphoma Treatment: Cell Therapy, Everything or Nothing?
    CHEN Fei-li, LI Wen-yu
    2022, 22(1): 38-40. DOI: 10.12019/j.issn.1671-5144.2022.01.009
    Abstract FullText HTML PDF
    2021 Clinical Research Advances in Lung Cancer
    ZHANG Chan-yuan, SU Jun-wei, CHEN Yu-qing, CHEN Hua-jun, YANG Jin-ji, WU Yi-long
    2022, 22(1): 41-45. DOI: 10.12019/j.issn.1671-5144.2022.01.010
    Abstract FullText HTML PDF
    2021 Clinical Research Advances in Tumor Radiotherapy
    TAN Pei-xin, PAN Yi
    2022, 22(1): 46-48. DOI: 10.12019/j.issn.1671-5144.2022.01.011
    Abstract FullText HTML PDF
    2021 Advances of Molecular Targeted Therapy for Hematologic Tumor
    ZHANG Yu-chen, DU Xin
    2022, 22(1): 49-52. DOI: 10.12019/j.issn.1671-5144.2022.01.012
    Abstract FullText HTML PDF
    2021 Progress in Treatment of Advanced Gastrointestinal Tumors
    MA Dong, YANG Dong-yang
    2022, 22(1): 53-55. DOI: 10.12019/j.issn.1671-5144.2022.01.013
    Abstract FullText HTML PDF
    2021 Significant Advances in Clinical Trials of Hepato-cellular Carcinoma
    YANG Yi-fan, CHEN Zi-de, CHEN Xiao-ming
    2022, 22(1): 56-58. DOI: 10.12019/j.issn.1671-5144.2022.01.014
    Abstract FullText HTML PDF
    2021 New Progress of Early Breast Cancer Treatment
    CHEN Xian-zhe, YANG Ci-qiu, WANG Kun
    2022, 22(1): 59-64. DOI: 10.12019/j.issn.1671-5144.2022.01.015
    Abstract FullText HTML PDF